ARTICLE | Company News
Orion, Bayer deal
June 13, 2016 7:00 AM UTC
The partners added the joint development of Orion’s ODM-201 to treat metastatic hormone-sensitive prostate cancer to a 2014 deal in metastatic castration-resistant prostate cancer (CRPC). The oral a...